Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8775304 | 0.89 | KMT2A (0.57) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL4666968 | 0.87 | MEN1 (0.55) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL973673 | 0.87 | KMT2A (0.69) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL23731908 | 0.86 | KMT2A (0.54) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL5450997 | 0.85 | MEN1 (0.56) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL13998335 | 0.84 | TDP1 (0.49) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL3494672 | 0.84 | ALDH1A1 (0.53) | KMT2ANPC1TDP1MDM2ALDH1A1 | |
| SCHEMBL3589983 | 0.83 | KMT2A (0.51) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL3607036 | 0.83 | KMT2A (0.51) | KMT2AMEN1NPC1TDP1MMP8 | |
| SCHEMBL381114 | 0.83 | ALDH1A1 (0.55) | KMT2AMEN1NPC1TDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754252-B2 | Asymmetric cyclization processes using unsaturated nitro compounds | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-06-17 | — | — | US | disclosed |
| US-20100298576-A1 | ASYMMETRIC CYCLIZATION PROCESSES USING UNSATURATED NITRO COMPOUNDS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-11-25 | — | — | US | disclosed |
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-13 | — | — | US | disclosed |
| EP-1984355-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | Takeda Pharmaceutical Company Limited (JP) | 2008-10-29 | — | — | EP | disclosed |
| WO-2007094513-A2 | CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-23 | — | — | WO | disclosed |
| CN-1249033-C | Cyclic amp-specific phosphodiesterase inhibitors | ICOS CORP (US) | 2006-04-05 | — | — | CN | disclosed |
| CN-1434799-A | Cyclic amp-specific phosphodiesterase inhibitors | ICOS CORP (US) | 2003-08-06 | — | — | CN | disclosed |
| US-6569890-B2 | Antiinflamamtory agents | ICOS CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20030013754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | ICOS CORPORATION | 2003-01-16 | — | — | US | disclosed |
| EP-1244620-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2002-10-02 | — | — | EP | disclosed |
| US-6372777-B1 | ENZYME INHIBITORS TREATMENT OF INFLAMMATORY DISEASES AND OTHER DISEASES INVOLVING ELEVATED LEVELS OF CYTOKINES, AS WELL AS CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, | ICOS CORPORATION | 2002-04-16 | — | — | US | disclosed |
| WO-2001047880-A1 | CYCLIC AMP-SPECIFIC PHOSPHODIESTERASE INHIBITORS | ICOS CORPORATION (US) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121048-A1 | Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension | REN, AGTR1, AGTR2 | KMT2A 952/4885MEN1 750/4885NPC1 3189/4885 |
| US-20030013754-A1 | Cyclic AMP-specific phosphodiesterase inhibitors | PDE4A, PDE4B, PDE4C | KMT2A 3995/4885MEN1 3232/4885NPC1 4258/4885 |
| US-20100298576-A1 | ASYMMETRIC CYCLIZATION PROCESSES USING UNSATURATED NITRO COMPOUNDS | NQO1, COASY, NOS2 | KMT2A 3541/4885MEN1 3219/4885NPC1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.